Additional file 1: of Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

Additional file 1: of Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells

Jiao Wang (47178)
Kyle Lupo (6050258)
Andrea Chambers (6050261)
Sandro Matosevic (1275933)

December 2018

Figure S1. (A) Scheme of the synthesis of PBAE 447. (B) 1 H NMR spectra of PBAE 447 polymer in DMSO-...

Additional file 14 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors

Ming Yi (15051)
Mengke Niu (10161634)
Yuze Wu (13930958)
Hong Ge (69344)
Dechao Jiao (8465739)
Shuangli Zhu (195480)
Jing Zhang (23775)
Yongxiang Yan (7248605)
Pengfei Zhou (3223116)
Qian Chu (546702)
Kongming Wu (95075)

October 2022

Additional file 14. Figure S14. Reclustering analysis of tumor-infiltrating NK cells. (a) T-distribu...

Additional file 1: of Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy

Hyun Gul Yang (6738041)
Moon Cheol Kang (6738044)
Tae Yoon Kim (6738047)
Injung Hwang (6738050)
Hyun Tak Jin (6738056)
Young Chul Sung (205013)
Ki-Seong Eom (3690331)
Sae Won Kim (6738074)

May 2019

Figure S1.Histology of the primary biopsy specimens. Biopsied samples from brain lesion were stained...

Additional file 2: of Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

Naoyuki Sakamoto (518287)
Takeshi Ishikawa (518284)
Satoshi Kokura (518285)
Tetsuya Okayama (518288)
Kaname Oka (3558128)
Mitsuko Ideno (518289)
Fumiyo Sakai (3558131)
Akiko Kato (251448)
Masashige Tanabe (3558134)
Tatsuji Enoki (518286)
Junichi Mineno (15939)
Yuji Naito (518298)
Yoshito Itoh (156583)
Toshikazu Yoshikawa (12546)

August 2015

Figure S1. Representative flow cytometry dot-plots for each population of expanded cells in patient ...

Additional file 5: of Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

Naoyuki Sakamoto (518287)
Takeshi Ishikawa (518284)
Satoshi Kokura (518285)
Tetsuya Okayama (518288)
Kaname Oka (3558128)
Mitsuko Ideno (518289)
Fumiyo Sakai (3558131)
Akiko Kato (251448)
Masashige Tanabe (3558134)
Tatsuji Enoki (518286)
Junichi Mineno (15939)
Yuji Naito (518298)
Yoshito Itoh (156583)
Toshikazu Yoshikawa (12546)

August 2015

Table S3. Change in cytotoxic activity of PBMCs against K-562 cells during and after NK cell therapy

Additional file 3: of Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

Naoyuki Sakamoto (518287)
Takeshi Ishikawa (518284)
Satoshi Kokura (518285)
Tetsuya Okayama (518288)
Kaname Oka (3558128)
Mitsuko Ideno (518289)
Fumiyo Sakai (3558131)
Akiko Kato (251448)
Masashige Tanabe (3558134)
Tatsuji Enoki (518286)
Junichi Mineno (15939)
Yuji Naito (518298)
Yoshito Itoh (156583)
Toshikazu Yoshikawa (12546)

August 2015

Figure S2. Cytotoxic activity of the final product from patient 5 against K-562 cells. Mean cell dea...

Additional file 1 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Nina Lamers-Kok (14081102)
Denise Panella (14081105)
Anna-Maria Georgoudaki (8365098)
Haiping Liu (182575)
Didem Özkazanc (14081108)
Lucia Kučerová (14081111)
Adil Doganay Duru (8365119)
Jan Spanholtz (185249)
Monica Raimo (3465485)

November 2022

Additional file 1: Table S1. List of clinical trials with non-engineered NK cell therapies. N = 36 c...

Additional file 3 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Nina Lamers-Kok (14081102)
Denise Panella (14081105)
Anna-Maria Georgoudaki (8365098)
Haiping Liu (182575)
Didem Özkazanc (14081108)
Lucia Kučerová (14081111)
Adil Doganay Duru (8365119)
Jan Spanholtz (185249)
Monica Raimo (3465485)

November 2022

Additional file 3: Table S3. List of clinical trials with non-engineered combination NK cell therapi...

Additional file 2 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Nina Lamers-Kok (14081102)
Denise Panella (14081105)
Anna-Maria Georgoudaki (8365098)
Haiping Liu (182575)
Didem Özkazanc (14081108)
Lucia Kučerová (14081111)
Adil Doganay Duru (8365119)
Jan Spanholtz (185249)
Monica Raimo (3465485)

November 2022

Additional file 2: Table S2. List of clinical trials with engineered NK cell therapies. N = 53 clini...

Additional file 3: of Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy

Hyun Gul Yang (6738041)
Moon Cheol Kang (6738044)
Tae Yoon Kim (6738047)
Injung Hwang (6738050)
Hyun Tak Jin (6738056)
Young Chul Sung (205013)
Ki-Seong Eom (3690331)
Sae Won Kim (6738074)

May 2019

Table S1. Summary of adventitious agents screening in NK101 cell line (XLSX 11 kb

Additional file 4 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Nina Lamers-Kok (14081102)
Denise Panella (14081105)
Anna-Maria Georgoudaki (8365098)
Haiping Liu (182575)
Didem Özkazanc (14081108)
Lucia Kučerová (14081111)
Adil Doganay Duru (8365119)
Jan Spanholtz (185249)
Monica Raimo (3465485)

November 2022

Additional file 4: Table S4. List of clinical trials with engineered combination NK cell therapies. ...

Additional file 4: of Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy

Hyun Gul Yang (6738041)
Moon Cheol Kang (6738044)
Tae Yoon Kim (6738047)
Injung Hwang (6738050)
Hyun Tak Jin (6738056)
Young Chul Sung (205013)
Ki-Seong Eom (3690331)
Sae Won Kim (6738074)

May 2019

Table S2. Summary of gene expression profiles of NK101 and NK-92 by RNA-sequencing. (XLSX 2920âkb)...

Additional file 1 of NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer

Sara Santana-Hernández (15126150)
Jesús Suarez-Olmos (17724655)
Sonia Servitja (3562583)
Pau Berenguer-Molins (17724658)
Marcel Costa-Garcia (17724661)
Laura Comerma (8504493)
Anna Rea (17724664)
Julia Perera-Bel (17724667)
Silvia Menendez (203417)
Oriol Arpí (14988602)
Begoña Bermejo (740126)
María Teresa Martínez (6386345)
Juan Miguel Cejalvo (4020425)
Iñaki Comino-Méndez (14907879)
Javier Pascual (745964)
Emilio Alba (535706)
Miguel López-Botet (6547676)
Federico Rojo (163971)
Ana Rovira (163968)
Joan Albanell (163974)
Aura Muntasell (15126129)

January 2024

Additional file 1. Supplementary methods. Supplementary Figure 1. Clinicopathological features and D...

Additional file 1: of Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain

Se Lee (3503897)
Won Kang (3503891)
Yeup Yoon (607298)
Ju Jin (3503900)
Hye Song (3471059)
Jung Her (3503888)
Sang Kang (3503894)
Yu Hwang (3503882)
Kyeong Kang (3503885)
Kyeung Joo (3471071)
Do-Hyun Nam (184130)

December 2015

The ARRIVE Guidelines Checklist Animal Research: Reporting In Vivo Experiments. (PDF 813 kb

Additional file 1: of Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma

Jian Zhang (1682)
Hao Peng (231482)
Wen-Fei Li (3343967)
Yuan Zhang (41832)
Li-Zhi Liu (432696)
Li Tian (207552)
Ai-Hua Lin (432697)
Ying Sun (23237)
Jun Ma (9393)

December 2018

Table S1.Baseline characteristics of 6218 patients with locoregionally advanced nasopharyngeal carci...

Additional file 1: of Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells

Jiao Wang (47178)
Kyle Lupo (6050258)
Andrea Chambers (6050261)
Sandro Matosevic (1275933)

December 2018

Figure S1. (A) Scheme of the synthesis of PBAE 447. (B) 1 H NMR spectra of PBAE 447 polymer in DMSO-...

Additional file 14 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors

Ming Yi (15051)
Mengke Niu (10161634)
Yuze Wu (13930958)
Hong Ge (69344)
Dechao Jiao (8465739)
Shuangli Zhu (195480)
Jing Zhang (23775)
Yongxiang Yan (7248605)
Pengfei Zhou (3223116)
Qian Chu (546702)
Kongming Wu (95075)

October 2022

Additional file 14. Figure S14. Reclustering analysis of tumor-infiltrating NK cells. (a) T-distribu...

Additional file 1: of Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy

Hyun Gul Yang (6738041)
Moon Cheol Kang (6738044)
Tae Yoon Kim (6738047)
Injung Hwang (6738050)
Hyun Tak Jin (6738056)
Young Chul Sung (205013)
Ki-Seong Eom (3690331)
Sae Won Kim (6738074)

May 2019

Figure S1.Histology of the primary biopsy specimens. Biopsied samples from brain lesion were stained...

Additional file 2: of Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

Naoyuki Sakamoto (518287)
Takeshi Ishikawa (518284)
Satoshi Kokura (518285)
Tetsuya Okayama (518288)
Kaname Oka (3558128)
Mitsuko Ideno (518289)
Fumiyo Sakai (3558131)
Akiko Kato (251448)
Masashige Tanabe (3558134)
Tatsuji Enoki (518286)
Junichi Mineno (15939)
Yuji Naito (518298)
Yoshito Itoh (156583)
Toshikazu Yoshikawa (12546)

August 2015

Figure S1. Representative flow cytometry dot-plots for each population of expanded cells in patient ...

Additional file 5: of Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

Naoyuki Sakamoto (518287)
Takeshi Ishikawa (518284)
Satoshi Kokura (518285)
Tetsuya Okayama (518288)
Kaname Oka (3558128)
Mitsuko Ideno (518289)
Fumiyo Sakai (3558131)
Akiko Kato (251448)
Masashige Tanabe (3558134)
Tatsuji Enoki (518286)
Junichi Mineno (15939)
Yuji Naito (518298)
Yoshito Itoh (156583)
Toshikazu Yoshikawa (12546)

August 2015

Table S3. Change in cytotoxic activity of PBMCs against K-562 cells during and after NK cell therapy

Additional file 3: of Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

Naoyuki Sakamoto (518287)
Takeshi Ishikawa (518284)
Satoshi Kokura (518285)
Tetsuya Okayama (518288)
Kaname Oka (3558128)
Mitsuko Ideno (518289)
Fumiyo Sakai (3558131)
Akiko Kato (251448)
Masashige Tanabe (3558134)
Tatsuji Enoki (518286)
Junichi Mineno (15939)
Yuji Naito (518298)
Yoshito Itoh (156583)
Toshikazu Yoshikawa (12546)

August 2015

Figure S2. Cytotoxic activity of the final product from patient 5 against K-562 cells. Mean cell dea...

Additional file 1 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Nina Lamers-Kok (14081102)
Denise Panella (14081105)
Anna-Maria Georgoudaki (8365098)
Haiping Liu (182575)
Didem Özkazanc (14081108)
Lucia Kučerová (14081111)
Adil Doganay Duru (8365119)
Jan Spanholtz (185249)
Monica Raimo (3465485)

November 2022

Additional file 1: Table S1. List of clinical trials with non-engineered NK cell therapies. N = 36 c...

Additional file 3 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Nina Lamers-Kok (14081102)
Denise Panella (14081105)
Anna-Maria Georgoudaki (8365098)
Haiping Liu (182575)
Didem Özkazanc (14081108)
Lucia Kučerová (14081111)
Adil Doganay Duru (8365119)
Jan Spanholtz (185249)
Monica Raimo (3465485)

November 2022

Additional file 3: Table S3. List of clinical trials with non-engineered combination NK cell therapi...

Additional file 2 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Nina Lamers-Kok (14081102)
Denise Panella (14081105)
Anna-Maria Georgoudaki (8365098)
Haiping Liu (182575)
Didem Özkazanc (14081108)
Lucia Kučerová (14081111)
Adil Doganay Duru (8365119)
Jan Spanholtz (185249)
Monica Raimo (3465485)

November 2022

Additional file 2: Table S2. List of clinical trials with engineered NK cell therapies. N = 53 clini...

Additional file 3: of Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy

Hyun Gul Yang (6738041)
Moon Cheol Kang (6738044)
Tae Yoon Kim (6738047)
Injung Hwang (6738050)
Hyun Tak Jin (6738056)
Young Chul Sung (205013)
Ki-Seong Eom (3690331)
Sae Won Kim (6738074)

May 2019

Table S1. Summary of adventitious agents screening in NK101 cell line (XLSX 11 kb

Additional file 4 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Nina Lamers-Kok (14081102)
Denise Panella (14081105)
Anna-Maria Georgoudaki (8365098)
Haiping Liu (182575)
Didem Özkazanc (14081108)
Lucia Kučerová (14081111)
Adil Doganay Duru (8365119)
Jan Spanholtz (185249)
Monica Raimo (3465485)

November 2022

Additional file 4: Table S4. List of clinical trials with engineered combination NK cell therapies. ...

Additional file 4: of Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy

Hyun Gul Yang (6738041)
Moon Cheol Kang (6738044)
Tae Yoon Kim (6738047)
Injung Hwang (6738050)
Hyun Tak Jin (6738056)
Young Chul Sung (205013)
Ki-Seong Eom (3690331)
Sae Won Kim (6738074)

May 2019

Table S2. Summary of gene expression profiles of NK101 and NK-92 by RNA-sequencing. (XLSX 2920âkb)...

Additional file 1 of NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer

Sara Santana-Hernández (15126150)
Jesús Suarez-Olmos (17724655)
Sonia Servitja (3562583)
Pau Berenguer-Molins (17724658)
Marcel Costa-Garcia (17724661)
Laura Comerma (8504493)
Anna Rea (17724664)
Julia Perera-Bel (17724667)
Silvia Menendez (203417)
Oriol Arpí (14988602)
Begoña Bermejo (740126)
María Teresa Martínez (6386345)
Juan Miguel Cejalvo (4020425)
Iñaki Comino-Méndez (14907879)
Javier Pascual (745964)
Emilio Alba (535706)
Miguel López-Botet (6547676)
Federico Rojo (163971)
Ana Rovira (163968)
Joan Albanell (163974)
Aura Muntasell (15126129)

January 2024

Additional file 1. Supplementary methods. Supplementary Figure 1. Clinicopathological features and D...

Additional file 1: of Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain

Se Lee (3503897)
Won Kang (3503891)
Yeup Yoon (607298)
Ju Jin (3503900)
Hye Song (3471059)
Jung Her (3503888)
Sang Kang (3503894)
Yu Hwang (3503882)
Kyeong Kang (3503885)
Kyeung Joo (3471071)
Do-Hyun Nam (184130)

December 2015

The ARRIVE Guidelines Checklist Animal Research: Reporting In Vivo Experiments. (PDF 813 kb

Additional file 1: of Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma

Jian Zhang (1682)
Hao Peng (231482)
Wen-Fei Li (3343967)
Yuan Zhang (41832)
Li-Zhi Liu (432696)
Li Tian (207552)
Ai-Hua Lin (432697)
Ying Sun (23237)
Jun Ma (9393)

December 2018

Table S1.Baseline characteristics of 6218 patients with locoregionally advanced nasopharyngeal carci...

Additional file 1: of Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells

Jiao Wang (47178)
Kyle Lupo (6050258)
Andrea Chambers (6050261)
Sandro Matosevic (1275933)

December 2018

Figure S1. (A) Scheme of the synthesis of PBAE 447. (B) 1 H NMR spectra of PBAE 447 polymer in DMSO-...

Additional file 14 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors

Ming Yi (15051)
Mengke Niu (10161634)
Yuze Wu (13930958)
Hong Ge (69344)
Dechao Jiao (8465739)
Shuangli Zhu (195480)
Jing Zhang (23775)
Yongxiang Yan (7248605)
Pengfei Zhou (3223116)
Qian Chu (546702)
Kongming Wu (95075)

October 2022

Additional file 14. Figure S14. Reclustering analysis of tumor-infiltrating NK cells. (a) T-distribu...

Additional file 1: of Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy

Hyun Gul Yang (6738041)
Moon Cheol Kang (6738044)
Tae Yoon Kim (6738047)
Injung Hwang (6738050)
Hyun Tak Jin (6738056)
Young Chul Sung (205013)
Ki-Seong Eom (3690331)
Sae Won Kim (6738074)

May 2019

Figure S1.Histology of the primary biopsy specimens. Biopsied samples from brain lesion were stained...

Additional file 1: of Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

Abstract

Extracted data

Additional file 1: of Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

Abstract

Extracted data

Related items

Related items